[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"supraventricular-tachycardia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:supraventricular-tachycardia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,76,102,130,150,184],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100462076","localization-of-anatomical-structures-involved-in-nodal-tachycardias-by-high-density-mapping-100462076",false,"NCT05296954","Localization of Anatomical Structures Involved in Nodal Tachycardias by High Density Mapping.","Localization of Anatomical Structures Involved in Nodal Tachycardias by High Density Mapping. Feasibility Study.","KOCH-MAPPING","Inclusion Criteria:\n\nGroup 1: Patients without heart disease presenting with reciprocal tachycardia by intra-nodal reentry.\n\nGroup 2: Control subjects, without nodal tachycardia, without heart disease, and admitted for ablation of atrial fibrillation or ventricular extrasystoles on a healthy heart and with a 3D system.\n\nExclusion Criteria:\n\n* Presence of underlying structural heart disease or history of atrial ablation or atrial tachycardia\n* Minor or protected patient\n* Patient under guardianship, curatorship or safeguard of justice","ALL","18 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of the present work is to analyze the capacity of high resolution mapping systems to determine the precise location of the AV node and peri-nodal slow-conducting pathways, using standard recording parameters, but also off-line additional filter changes and additional techniques (conduction velocities, isochrones and dV\u002Fdt). The investigative team plan a prospective monocentric study.\n\nDetailed high resolution mapping of the Koch triangle and neighboring areas will be collected through the RHYTHMIA HDx 3D electro-anatomical mapping system and the multipolar ORION catheter. This sample will consist of 2 groups of patients: the first will include patients referred for AVNRT ablation and the second will include control patients (without AVNRT), referred for another indication requiring similar mapping system. If visualized, position of the slow pathway and AV node will be compared with the ablation areas, which will be set conventionally under fluoroscopy.",[27,28],"Atrioventricular Nodal Reentry Tachycardia","Supraventricular Tachycardia",[30,31],"Voltage mapping","Atrioventricular node mapping","RECRUITING","2026-05-28",{"date":35,"type":36},"2026-06-01","ACTUAL",{"date":38,"type":36},"2022-02-04",{"date":40,"type":21},"2026-12",{"name":42,"class":43},"University Hospital, Toulouse","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":44},"100640090","nasval-svt-nasal-swab-versus-modified-valsalva-for-supraventricular-tachycardia-100640090","NCT07617077","NASVAL-SVT: Nasal Swab Versus Modified Valsalva for Supraventricular Tachycardia","A Randomized Controlled Trial Comparing Nasal Swab and Modified Valsalva Maneuver for the Treatment of Supraventricular Tachycardia","NASVAL-SVT","Inclusion Criteria:\n\n* Age 18 years or older\n* Electrocardiographically confirmed supraventricular tachycardia (SVT): narrow QRS complex (≤120 ms), regular rhythm, rapid ventricular rate, documented on 12-lead ECG or continuous cardiac monitoring\n* Hemodynamic stability, defined as ALL of the following simultaneously present:\n* Systolic blood pressure ≥90 mmHg\n* Diastolic blood pressure ≥60 mmHg\n* Alert and oriented mental status (GCS 15)\n* No signs of acute end-organ dysfunction\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Pregnancy (known or suspected)\n* Inability to confirm SVT diagnosis by ECG criteria\n* Delta wave or pre-excitation pattern on ECG (Wolff-Parkinson-White syndrome or asymptomatic pre-excitation) - due to risk of ventricular fibrillation with vagal maneuvers\n* Wide QRS tachycardia (QRS ≥120 ms) where ventricular tachycardia cannot be excluded\n* Absolute contraindication to modified Valsalva maneuver (inability to assume supine position or passive leg elevation)\n* Contraindication to nasal swab (nasal surgery within 30 days, active epistaxis, visible nasal polyp or mass)\n* Hemodynamic instability requiring immediate synchronized cardioversion\n* Prior enrollment in this study (re-presentation with SVT)\n* Refusal to participate",{"count":54,"type":21},60,[24],"Supraventricular tachycardia (SVT) is a common heart rhythm disorder seen in emergency departments, causing a rapid heartbeat (typically 150-250 beats per minute). The current best non-drug treatment, the modified Valsalva maneuver (mVM), successfully restores normal rhythm in about 43% of cases. When these maneuvers fail, intravenous adenosine is used, which, while effective, can cause brief but distressing side effects such as chest tightness, shortness of breath, and intense anxiety.\n\nDuring the COVID-19 pandemic, some patients briefly fainted during nasal swab collection. This happens because inserting a swab into the back of the nasal cavity (nasopharynx) stimulates the trigeminal nerve, which then activates the vagus nerve and slows the heart - a phenomenon called the trigeminocardiac (or nasocardiac) reflex. One published case report described a patient whose SVT was terminated within 10 seconds using a nasal swab.\n\nThis study compares the nasal swab technique with the modified Valsalva maneuver in patients presenting to the emergency department with SVT. Patients are randomly assigned to one of two groups. The primary outcome is whether a normal heart rhythm is restored within 1 minute of the procedure. Patient comfort and satisfaction are also measured.\n\nThe study is conducted in two phases. The first (pilot) phase (30 patients per group) will assess whether the study can be successfully conducted and collect data to finalize the required sample size. The second (main) phase will use the pilot phase's actual data to determine the final number of participants needed.",[28,58,27,59],"Paroxysmal Supraventricular Tachycardia","Vagal Maneuver",[61,62,63,64,65,66,67],"SVT","nasal swab","nasocardiac reflex","trigeminocardiac reflex","Valsalva maneuver","REVERT","emergency department","2026-05-23",{"date":35,"type":36},{"date":71,"type":36},"2026-05-01",{"date":73,"type":21},"2027-06",{"name":75,"class":43},"Marmara University Pendik Training and Research Hospital",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":100,"locationsCount":44},"100604393","validity-and-algorithm-development-for-detection-of-supraventricular-tachycardia-in-children-a-clinical-pilot-study-100604393","NCT07148934","Validity and Algorithm Development for Detection of Supraventricular Tachycardia in Children-A Clinical Pilot Study","Inclusion Criteria:\n\n* For children in Study(SVT) group:\n\n  1. received informed consent from both parents\u002Fguardians\n  2. the child is treated in the Pediatric wards of Tyks Lighthouse hospital\n  3. the child is between the age of 0-10 years\n  4. the child has diagnosed or suspected SVT.\n* For children in control group:\n\n  1. received informed consent from both parents\u002Fguardians\n  2. the child is treated in the Pediatric wards of Tyks Lighthouse hospital\n  3. the child is between the age of 0-10 years\n  4. child has not diagnosed with SVT\n\nExclusion Criteria:\n\n* All participant groups:\n\n  1. not reaching the inclusion criteria","0 Years","10 Years",{"count":54,"type":21},"OBSERVATIONAL","The aim of this study is to evaluate the reliability of smartphone seismocardiography (SCG) and bed-based ballistocardiography (BCG) for detecting supraventricular tachycardia (SVT) in children aged 0-10 years. The performance of these methods will be compared to the gold standard of continuous telemetry ECG recording.",[28,88],"Atrial Fibrillation (AF)",[28,90,91,92],"Atrial Fibrillation","Seismocardiography","SmartPhone","NOT_YET_RECRUITING","2026-04-09",{"date":96,"type":36},"2026-04-13",{"date":98,"type":21},"2026-04",{"date":73,"type":21},{"name":101,"class":43},"University of Turku",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":109,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":44},"100612987","evaluation-of-a-single-lead-ecg-patch-based-telemetry-system-for-in-hospital-monitoring-100612987","NCT07260721","Evaluation of a Single-lead ECG Patch-based Telemetry System for In-hospital Monitoring","Investigator-initiated Trial to Evaluate the Performance and Utility of a Single-lead Electrocardiogram Patch-based Telemetry System in Patients Requiring In-hospital Telemetry Electrocardiogram Monitoring During Hospitalization","Inclusion Criteria:\n\n* Adults aged 19 years or older who provide written informed consent for participation.\n* Patients requiring in-hospital telemetry electrocardiogram monitoring during hospitalization.\n\nExclusion Criteria:\n\n* Known hypersensitivity or allergic reaction to adhesives or hydrogel.\n* Presence of skin wounds at the intended application site of the investigational device.\n* Implanted cardiac electronic devices such as pacemakers, ICDs, or other CIEDs\n* Current or past history of skin cancer, rash, dermatologic disorders, keloid formation, or skin injury.\n* Any condition judged by the investigator to increase risk or make participation inappropriate.\n* Cognitive impairment that precludes understanding of study information or voluntary consent.","19 Years",{"count":111,"type":21},100,[24],"\"This investigator-initiated, prospective, single-center clinical study evaluates the performance and clinical utility of a single-lead electrocardiogram (ECG) patch-based telemetry system for hospitalized patients who require in-hospital telemetry ECG monitoring. The system integrates real-time centralized surveillance (MEMO-Cue) with post-hoc analytic review (MEMO-Care) using ECG signals recorded by the MEMO Patch M, aiming to enable timely recognition of clinically important arrhythmias and to inform treatment decisions under routine inpatient conditions.\n\nAdults (≥19 years) indicated for continuous ECG monitoring during admission are enrolled after written informed consent, with a planned sample size of 100 to yield approximately 90 evaluable participants (10% anticipated dropout). The design does not include randomization or blinding. Study procedures include a screening visit (eligibility and baseline data), an inpatient monitoring period of at least 12 hours and up to 8 days with simultaneous MEMO-Cue monitoring and MEMO Patch M recording, and an end-of-visit assessment when MEMO-Care analytic results become available. Concomitant therapies deemed clinically necessary are permitted and documented, and adverse events are prospectively assessed.\n\nClinical utility endpoints quantify care impact and timeliness: (1) rate of treatment plan changes (e.g., initiation or modification of anticoagulants or antiarrhythmic drugs, cardioversion scheduling, device implantation, or other actions); (2) time to recognition (days) of major arrhythmias-atrial fibrillation (AF), ventricular tachycardia (VT), pause, ventricular premature complex (VPC), and supraventricular tachycardia (SVT)-based on MEMO-Cue alarms or MEMO-Care results with objective confirmation; (3) reduction ratio in recognition time when identified earlier by MEMO-Cue versus MEMO-Care; and (4) proportion of participants with shortened recognition time by MEMO-Cue.\n\nClinical performance endpoints assess detection characteristics and agreement between MEMO-Cue alarms and MEMO-Care findings: (1) clinical sensitivity (true positive \u002F \\[true positive + false negative\\]); (2) precision, i.e., positive predictive value (true positive \u002F \\[true positive + false positive\\]); and (3) positive concordance rate (proportion of MEMO-Care-detected arrhythmias alerted by MEMO-Cue). Safety is captured as treatment-emergent adverse events after device application, including device-related skin reactions, detachment, or signal dropouts, with severity graded per NCI-CTCAE v5.0 and relationship to device recorded.\n\nBy characterizing real-time patch-based telemetry alongside analytic review and its influence on diagnostic timing and management, the study aims to generate practical evidence supporting feasibility, reliability, and workflow compatibility of single-lead patch telemetry for in-hospital ECG monitoring.",[115,90,116,28,117,118,119,120],"Arrhythmias","Ventricular Tachycardia","Bradycardia","Telemetry","Patient Monitoring","Hospitalization","2025-12-01",{"date":123,"type":36},"2025-12-03",{"date":125,"type":21},"2025-12",{"date":127,"type":21},"2026-09",{"name":129,"class":43},"Yonsei University",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":137,"maxAge":18,"enrollmentInfo":138,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":4},"100603982","outcome-of-svt-in-children-admitted-to-auch-100603982","NCT07143591","Outcome of SVT in Children Admitted to AUCH","Outcome of Supraventricular Tachycardia in Children Admitted to Assuit University Children Hospital","Inclusion Criteria:\n\n* Children aged greater than 1 month and up to 18 years\n* Diagnosis of supraventricular tachycardia (SVT) based on:\n* Clinical presentation\n* Electrocardiogram (ECG) findings\n\nExclusion Criteria:\n\n* Presence of structural heart disease\n* Incomplete clinical data\n* Lost to follow-up during the study period","1 Month",{"count":54,"type":21},"The aim of the study is to:\n\n. Assess the outcome of Supraventricular tachycardia , the most effective acute and long-term management strategies and recurrence rates of SVT .",[28],"2025-08-26",{"date":143,"type":36},"2025-09-02",{"date":145,"type":21},"2025-08",{"date":147,"type":21},"2026-08",{"name":149,"class":43},"Assiut University",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":161,"conditions":162,"keywords":167,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":183},"100594377","clinical-safety-and-efficacy-testing-of-a-medical-device-kardi-ai-an-ecg-telemetry-monitoring-system-100594377","NCT07018648","Clinical Safety and Efficacy Testing of a Medical Device Kardi Ai, an ECG Telemetry Monitoring System","Clinical Safety and Efficacy Testing of a Medical Device Kardi Ai, an ECG Telemetry Monitoring System Using Artificial Intelligence to Evaluate ECGs Measured by Hardware Component (POLAR H10 Chest Strap)","Kardi Ai","Inclusion Criteria:\n\n* Age above 18 years\n* Signed informed consent\u002Fwillingness to cooperate\n* Confirmed or suspected heart rhythm disorder of a cardiac rhythm disorder\n* Ability to use a smartphone and mobile app Kardi Ai\n* The subject's mobile phone meets the minimum requirements for the Kardi Ai app to work\n\nExclusion Criteria:\n\n* Confirmed pregnancy\n* Allergic reactions to standard substances used in manufacture of clothing or other textiles\n* Superficial wound or skin irritation at the site of the chest belt attachment",{"count":159,"type":21},115,[24],"The goal of this clinical trial is to evaluate the safety and efficacy of medical device Kardi Ai, an ECG telemetry monitoring device in adult population.\n\nThe main questions it aims to answer are:\n\n* What is the sensitivity and specificity of Kardi Ai device for all monitored heart rythm disorders (combined)\n* What is the sensitivity and specificity of Kardi Ai device for each of the monitored heart rythm disorders\n* What is the quality of the ECG recordings\n\nParticipants will receive Kardi Ai medical device. They will use it to collect ECG recordings from at least 5 different days and in total collect records of at least 10 hours duration.",[88,163,164,117,165,28,166],"Atrial Premature Complexes","Ventricular Premature Complexes","Tachycardia","Wide QRS Tachycardia",[168,169,170,171,172],"AI","heart rhythm disorders","ECG","EKG","atrial fibrillation","2025-06-10",{"date":175,"type":36},"2025-06-12",{"date":177,"type":36},"2025-05-19",{"date":179,"type":21},"2025-08-30",{"name":181,"class":182},"KARDI AI Technologies s.r.o.","INDUSTRY",2,{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":192,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":193,"targetDuration":83,"studyType":85,"phases":4,"briefSummary":195,"conditions":196,"keywords":206,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":44},"100479320","clinical-cohort-study---trust-100479320","NCT05521451","Clinical Cohort Study - TRUST","Longterm Outcome and Predictors for Recurrence After Medical and Interventional Treatment of Arrhythmias At the University Heart Center Hamburg","TRUST","Inclusion Criteria:\n\n* Cardiac arrhythmia, including congenital cardiac arrhythmia diagnosed at baseline or high risk for cardiac arrhythmia\n* Age ≥ 18 years\n* Written informed consent\n* Ability to provide written informed consent in accordance with Good Clinical Practice and local legislation\n\nExclusion Criteria:\n\n* Insufficient knowledge of the German language to understand study documents and interview without translation\n* Physical or psychological incapability to cooperate in the investigation",true,{"count":194,"type":21},5000,"The \"Long-term Outcome and Predictors for Recurrence after Medical and Interventional Treatment of Arrhythmias at the University Heart Center Hamburg\" (TRUST) study is an investor-initiated, single-center, prospective clinical cohort study including patients treated with cardiac arrhythmias or at high risk for cardiac arrhythmias. The design enables prospective, low-threshold, near complete inclusion of patients with arrhythmias treated at the UHZ. Collection of routine follow-up data, detailed procedural information and systematic biobanking will enable precise and robust phenotyping.",[197,90,198,116,199,200,201,202,28,203,204,205],"Arrhythmias, Cardiac","Atrial Flutter","Atrial Tachycardia","Arrhythmogenic Right Ventricular Dysplasia","Long QT Syndrome","Brugada Syndrome","Catecholaminergic Polymorphic Ventricular Tachycardia","Torsades De Pointes","Atrial Cardiomyopathy",[207,208,209,210,211,212,205],"Catheter Ablation","Biomarkers","Cardiac Arrhythmia","eHealth","Digital Cardiology","Echocardiography","2025-03-25",{"date":215,"type":36},"2025-03-30",{"date":217,"type":36},"2021-03-17",{"date":219,"type":21},"2031-12-31",{"name":221,"class":43},"Universitätsklinikum Hamburg-Eppendorf"]